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TH effects of PDE inhibitors on oxazolone-induced con-
tact hypersensitivity (CS) were studied in mice. Rolipram,
Ro 20-1724 and theophylline dose dependently inhibited
CS but none caused >53% inhibition. ED30 values at 24 h
before challenge for roHpram, Ro 20-1724 and
theophylline were 2.1, 5.4 and 30.4 mg/kg, p.o., respec-
tively. Milrinone and SKF 94836 at 30 mg/kg caused a
small, but significant inhibition of 13% and 18%, respec-
tively, although the inhibition (8%) caused by zaprinast
was not significant. Betamethasone (10 mg/kg, p.o.)
caused a marked inhibition (80%) as did indomethacin
(65% at 5 mg/kg, p.o.). SoHpram and So 20-1724 inhib-
ited proliferation ofmouse lymphoblasts with IC0 values
of 0.08 tM and 0.83 tM, respectively. In contrast,
zaprinast caused only aweak inhibition (IC0 119 tM) of
lymphocyte proliferation, whereas SKF 94836 and
theophylline failed to cause any significant inhibition at
100 tM (26% and 2%, respectively). These findings sug-
gest that PDE IV isozymes play a principal role in medi-
ating CS by inhibiting lymphocyte activation.
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Introduction
In inflammatory diseases such as allergic or contact
dermatitis, there is convincing evidence for the in-
volvement of activated leukocytes, such as
lymphocytes, eosinophils and monocytes. The regu-
lation of the activation state of these leukocytes
occurs at many levels. Evidence is now accumulating
that changes in the intracellular levels of cyclic
nucleotides, such as cyclic adenosine mono-
phosphate (cAMP) play an important role in the
regulation of inflammatory cell activity2,3 and that in
atopic dermatitis there is decreased cyclic nucleotide
phosphodiesterase (PDE) activity. In general, in-
creases in levels of cAMP result in a reduction in the
activity of inflammatory cells. The rate of breakdown
of cAMP is controlled by a family of five isozymes
collectively known as cyclic nucleotide
phosphodiesterases and are designated PDE to V.
These isozymes are classified according to their dif-
ferences in tissue distribution, kinetic and physical
characteristics, substrate selectivities, sensitivities to
endogenous activators and inhibitors, susceptibility
to phosphorylation by protein kinases and protein
sequences. PDE IV isozymes appear to a very large
extent to be present in inflammatory cells, such as
basophils, mast cells, neutrophils, monocytes and
eosinophils. In contrast there appears to be both PDE
III and PDE IV isozymes present in lymphocytes. 2,6,7
Cluster differentiation (CD) analysis has permitted
the classification of lymphocytes according to their
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different functions. Helper, CD4 lymphocytes are
involved in immediate hypersensitivity and both
CD4 and CD8 lymphocytes are involved in delayed
or contact type hypersensitivity. CD4 lymphocytes
have been differentiated into Thl and Th2 subtypes
according to their lymphokine production, at least in
the mouse. However, functional differentiation of
lymphocytes has also been demonstrated in patients
with infections and allergies.
1
The purpose of this study was to investigate to
what extent selective PDE inhibitors, milrinone and
SKF 94836 (PDE liD, Rolipram and Ro 20-1724 (PDE
IV), zaprinast (PDE V) and the non-selective PDE
inhibitor, theophylline, were capable of modulating
oxazalone-induced ear oedema in the mouse, an
animal model of contact hypersensitivity. Such a
study could thus provide a tentative insight into the
relative importance of PDE isozymes in modulating
the activity of subsets of lymphocytes that mediate
the contact hypersensitivity response.
Materials and Methods
Mice: Male Swiss mice (16-18 g on arrival) and fe-
male, C57B16 (5-6 weeks old) were used for the
contact hypersensitivity and lymphoblast transforma-
tion experiments, respectively, and were purchased
from IFFA CREDO, France. The animals were accli-
matized for a period of 4-7 days prior to use, at an
ambient temperature of 21C under artificial light
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with a 12 h cycle. Food (with added vitamins, Al14,
UAR) and water was available ad libitum.
Contact hypersensitivity: Mice were sensitized by
application of 0.1 ml of 2% (w/v) oxazolone (4-
ethoxymethylene-2-phenyl-2-oxazol-5-one, Sigma
Chemicals, MO, USA) in olive oil to the shaved
abdominal area. Seven days later mice were chal-
lenged with oxazolone 2% (w/v), in a vehicle con-
sisting of 2-methoxyethanol:95% ethanol:Tween 80
(45:45:10), applied externally on the inside surface of
the right ear, and vehicle alone to the left ear.
Volumes of administration were 10 btl/ear.
Measurements: Ear thickness was measured at 6 h
and 24 h after challenge. Both ears were measured
using a micrometer (Digitrix II, Helios W5126001)
and the difference in volume between the two ears
were noted for further analysis. Animals were anaes-
thetized with pentobarbital for the 6 h measurement
and sacrificed by cervical dislocation for the 24 h
measurement.
Treatment: PDE inhibitors or glucorticosteroids were
given orally as a single administration either at 24 h
or 3 h before challenge or 3 h after challenge.
Statistical evaluation: Results were analysed statisti-
cally using the unpaired Student’s t-test. In each
treatment group there were ten mice. Values are
means of three separate experiments.
Lymphoblast transformation: Mice were sacrificed by
decapitation. Thymus glands were removed and
placed in Spinner modified minimal essential me-
dium (SMEM) supplemented with 1% v/v non-essen-
tial amino acids, 1.2 mM t-glutamate, 1 mM sodium
pyruvate, 100 U/ml penicillin, 100 btg/ml streptomy-
cin and 5% Ultroser, cleaned of adherent connective
tissue and placed on a 40 micron mesh nylon gauze
and dispersed with the aid of a piston from a 5 ml
syringe. The cell suspension was then centrifuged at
250 x g for 10 min at 4C and resuspended in SMEM.
The viability of the cells assessed by Trypan Blue
exclusion were usually >90%. Aliquots containing
1 x 106 cells were distributed into 96-well fiat-bot-
tomed microtitre plates (Falcon) and incubated for 24
h at 37C in a humidified atmosphere of 95% air and
5% CO2 in the presence of concanavalin A (5 t.tg/ml)
and appropriate concentrations of the different types
of PDE inhibitors dissolved in dimethyl sulphoxide
which had a final concentration of 0.25% v/v in the
incubation medium and did not affect the prolifera-
tive response. Following the addition of [3H]-
thymidine (0.1 Ci), the cells were then incubated for
a further 24 h. Cells were then collected onto glass
fibre filters (GF/A, Whatman) with the aid of a PHD
Cell Harvester and placed into scintillation vials con-
taining Scintillator Plus (Packard) for counting in
Betamatic Scintillation Counter (Kontron) for 1 min.
Statistical evaluation: Each PDE inhibitor was exam-
ined in triplicate on thymus cell preparations from
three mice. Percentage inhibition was calculated with
respect to vehicle treated controls and IC50 values
determined where applicable and analysed statisti-
cally using Dunnett’s test.
Materials: Theophylline, milrinone and
indomethacin were purchased from Sigma Chemi-
cals, MO, USA; pentobarbital from Sanofi, France. Ro
20-1724 was from RBI. SKF 94836 and zaprinast were
generous gifts from Smith Kline & Beecham and
Rhone-Poulenc-Rorer, UK. Rolipram, prednisolone
and betamethasone were synthesized at Institut de
Recherche Jouveinal.
SMEM, non-essential amino acids, t-glutamate,
sodium pyruvate, penicillin and streptomycin were
purchased from Gibco, France. Ultroser and PH]-
thymidine were purchased from Sepracor, France
and NEN, Belgium, respectively.
Results
Effect of PDE inhibitors on the inhibition of
oxazolone-induced er-swelling in mice, measured
at 6 h or 24 h after challenge: The selective PDE IV
inhibitors, rolipram and Ro 20-1724 as well as the
non-selective PDE inhibitor, theophylline, adminis-
tered 24 h before challenge caused a dose-depend-
ent inhibition of oxazolone-induced ear swelling
measured either at 6 h or 24 h after challenge (Table
1). The effects were more pronounced when ear
swelling was measured 24 h after challenge. How-
ever, even at maximal doses, these PDE inhibitors
failed to cause more than 53% inhibition.
Indomethacin also caused a dose-related inhibition
that did not appear to be dependent on the time of
measurement. Furthermore, at the highest dose of
indomethacin, inhibition of ear swelling was 66%
and 60%, measured either at 6 h or 24 h after chal-
lenge. Thus for theophylline and the selective PDE IV
inhibitors and indomethacin ED0 values (i.e., the
dose in mg/kg resulting in 30% inhibition) were
determined as shown in Table 2. The order of po-
tency was indomethacin > rolipram > Ro20-1724>
theophylline, the activity of the PDE inhibitors being
greater when measured 24 h after challenge as
mentioned above.
Effect of time of administration of selective PDE in-
hibitors on oxazolone-induced ear-swelling in mice,
measured 24 h after challenge: For these experi-
ments all measurements of ear swelling were made
24 h after challenge and the test compounds were
administered at 3 h or 24 h before challenge or 3 h
after challenge. The results are shown in Table 3.
Theophylline appeared to be more active when ad-
ministered either 24 h or 3 h before challenge. The
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Table 1. Effect of selective PDE inhibitors on inhibition of oxazolone-induced ear-swelling in mice, measured at 6 h
or 24 h after challenge
Compounds Dose Inhibition (%)
(mg/kg, p.o.)
6 h after challenge 24 h after challenge
challenge
10 -5.8 (ns) 12.8 (ns)
Theophylline 30 11.1 (ns) 33.0***
100 39.9*** 45.2***
10.6 (ns) 20.2**
Rolipram 3 27.5** 35.4"**
5 38.6*** 40.8***
3 14.1 (ns) 24.3***
Ro 20-1724 10 24.5** 34.5***
30 37.2*** 53.1
0.5 2.3 (ns) 13.7"
ndomethacin 24.1 33.9***
3 33.2*** 39.7***
5 65.5*** 59.3***
Prednisolone 5 25.4"* 38.3***
Compounds administered 24 h before challenge, n 3, each group consisted of ten mice.
*p < 0.05, **p < 0.01; ***p < 0.001. ns, not significant.
Table 2. EDo values for selective PDE inhibitors administered
24 h before challenge
Compounds EDao values
6 h after challenge 24 h after challenge
Rolipram 3.2 2.1
Ro 20-1724 15.4 5.4
Theophylline nd 30.4
Indomethacin 1.6 1.1
nd not done.
activity Ro 20-1724 was similar regardless of times of
administration. In contrast, rolipram appeared to be
more active when administered either 24 h before or
3 h after challenge. The selective PDE III inhibitors,
milrinone and SK&F 94836 and the PDE V inhibitors,
zaprinast caused a smaller, but significant, inhibition
and appeared to be more active when administered
3 h after challenge. For purposes of comparison, the
glucocorticoid, betamethasone was also studied and
caused a marked inhibition (77%) when adminis-
tered 3 h before challenge. These differences in
activity in relation to time of administration may
reflect differences in metabolism or modulation of
the activity of inflammatory cells at different levels of
activation states following challenge.
Effect ofPDE inhibitors on concanavalin A induced
proliferation of mouse lymphoblasts: The effects of
selective PDE inhibitors were studied on mitogen-
induced thymocyte proliferation as a model of T cell
activation. The results are shown in Table 4. Rolipram
and Ro 20-1724 inhibited proliferation of mouse
lymphoblasts with IC50 values of 0.08 btM and 0.83
btM, respectively. In contrast, zaprinast caused only a
weak inhibition (IC50 119 ].tM), whereas SKF 94836
and theophylline failed to cause any significant inhi-
bition at 100 laM (26% and 2%, respectively).
Table 3. Effect of selective PDE inhibitors following different times of administration on oxazolone-induced ear-swelling
in mice, measured 24 h after challenge
Compounds Dose Inhibition(%)
(mg/kg,
p.o.) 24 h before 3 h before 3 h after
challenge challenge challenge
Rolipram 5 34.2*** 27.0"** 42.5***
Ro 20-1724 30 47.5*** 45.4*** 45.2***
Theophylline 100 51.5*** 52.9*** 33.0"**
SKF 94836 30 13.4" 13.4" 22.2***
Milrinone 30 19.4"* 19.8"* 29.5***
Zaprinast 30 8.1 (ns) 13.9" 21.7"*
Betamethasone 10 20.7** 76.7*** nd
n 3, each group consisted of ten mice.
nd not determined.
ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001.
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Table 4. Effect of selective PDE inhibitors on concanavalin A-
induced proliferation of mouse thymocytes.
Compounds ICo (pM)
Mean + S.D.
Rolipram 0.08 + 0.06 10
Ro 20-1724 0.83 + 0.49 5
Milrinone 3.96
SKF 94836 >>100 2
Zaprinast 119.3 + 53.7 5
n number of experiments.
Discussion
Cutaneous hypersensitivity responses with de-
layed kinetics are known as delayed type
hypersensitivity (DTH) and contact sensitivity (CS)
responses. These two types of hypersensitivity re-
sponses are characterized by the presence of
lymphocytes and monocytes at the site of sensitiv-
ity011’12 In this work the effects of selective PDE
inhibitors on oxazolone-induced contact hyper-
sensitivity were studied in the mouse.
To our knowledge the PDE isozyme profile in
mouse lymphocytes has not been studied. However,
the PDE isozyme profiles of lymphocytes from rats2,6
and humans have been characterized. In rat
lymphocytes types I, II, III, IV and V PDE isozymes
have been identified. In human lymphocytes only
types III and IV have been identified through partial
characterization. In addition, in human T-cell lines, a
rolipram insensitive, specific cAMP PDE has been
identified. In terms of activation of lymphocytes by
T-cell specific mitogens, PDE IV and to a lesser extent
PDE III inhibitors attenuate the proliferative response
through elevation of intracellular cAMP. Elevation of
intracellular cAMP appears to differentially regulate
the activity of Thl and Th2. Forskolin or cholera
toxin, agents that cause an increase in intracellular
cAMP, inhibit proliferation and generation of IL-2 in
Thl cell lines but not proliferation and generation of
IL-4 in Th2 cell lines.1 However, elevation of cAMP
through PDE inhibitors blocks the proliferative re-
sponse in both Thl and Th2 cell lines. Thus it
appears that elevation of intracellular cAMP at one
level may be occurring in discrete pools and thus be
able to control the activation state of different subsets
of lymphocytes in a relatively precise manner. The
response of different subsets of lymphocytes follow-
ing sensitization with oxazolone has been studied.
Three days after sensitization, CD4 and CD8
lymphocytes were isolated from draining lymph
nodes and their lymphokine production assessed. At
this stage CD4 Thl lymphocytes appear to be impor-
tant since IL-4 is necessary for transfer.
Our results on concanavalin A-induced prolifera-
tion of mouse lymphoblasts suggest that with the aid
of selective PDE inhibitors the principal isozymes
involved belong to the PDE IV subclass. As in the
case for rat and human lymphocytes, PDE III
isozymes also appear to contribute to some extent to
the inhibition of mitogen-stimulated proliferative re-
eponses. In a manner similar to the effects of
lymphocyte proliferation, we found that the selective
PDE IV inhibitors, rolipram and Ro 20-1724 were the
most potent inhibitors of oxazolone-induced
hypersensitivity. However, this inhibitory effect was
never greater than 50% and certainly much less than
that obtained with the corticosteroid, betamethasone
or the cyclooxygenase inhibitor, indomethacin.
These results suggest that in vivo that PDE IV
isozymes also play an important role in regulating the
activity of T-cell mediated responses. However, since
milrinone, SKF 94836 and zaprinast caused small but
significant inhibitions, there seems to be some role
for PDE III and PDE V isozymes. However, the
inhibitory effect of SKF 94836 could be attributed to
vascular vasodilatation, whilst that observed with
milrinone (30%) may be accounted for by the fact
that this compound also has an inhibitory effect on
PDE IV isozymes (unpublished observations). The
effect of zaprinast could be attributed to the inhibi-
tion of mediator release from mast cells,
14 one of the
effector cells in the CS response known to contain
PDE V isozymes. Nevertheless, since only partial
inhibition was achieved by PDE IV inhibitors, there
are likely to be other second messenger pathways
involved in T-cell activation, 15 or alternatively only
certain subsets of lymphocytes are sensitive to
changes in intracellular cAMP levels.,1,16 The fact that
the CS response can be inhibited to a greater extent
by indomethacin and almost completely by
betamethasone lends further support to these two
suggestions. These observations taken together and
the fact that PDE IV inhibitors are more potent at
inhibiting the latter phase of the CS response sug-
gests that these agents are acting mainly at the level
of T cells.
In conclusion, PDE IV isozymes over and above
other PDE isozyme subtypes, appear to play a major
role in mediating CS responses. Since these PDE IV
inhibitors in general are relatively weak inhibitors of
the CS response and of the mitogen-induced T-cell
proliferative response, these agents are likely to have
poor immunosuppressant properties. In contrast,
selective PDE IV inhibitors have been shown to have
potent antiinflammatory effects in models of asthma
in guinea-pigs
17 and inhibit IgE synthesis from hu-
man cells.
18 Therefore, these agents are likely to have
greater potential as antiasthmatic agents but without
the immunosuppressive effects of corticosteroids.
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